TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Recommendation of “Moderate Buy” by Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has been assigned an average rating of “Moderate Buy” from the eleven brokerages that are covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $122.70.

TMDX has been the topic of several research reports. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. TD Cowen lowered their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Piper Sandler cut their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Robert W. Baird lowered their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Finally, Canaccord Genuity Group lowered their target price on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th.

TransMedics Group Stock Performance

TMDX stock opened at $67.46 on Friday. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of 71.77 and a beta of 2.12. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group has a twelve month low of $55.00 and a twelve month high of $177.37. The business’s fifty day simple moving average is $68.30 and its two-hundred day simple moving average is $97.72.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TMDX. Atlas Capital Advisors Inc. acquired a new position in shares of TransMedics Group in the 4th quarter valued at $31,000. Hager Investment Management Services LLC acquired a new stake in shares of TransMedics Group during the 4th quarter valued at about $33,000. Sachetta LLC purchased a new position in shares of TransMedics Group in the 4th quarter valued at about $40,000. AlphaQuest LLC purchased a new position in TransMedics Group during the fourth quarter worth approximately $52,000. Finally, Quarry LP increased its position in shares of TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after buying an additional 312 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.